Drug
Bn80927
Bn80927: highest development phase Phase 1, developed by Ipsen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| BN80927 NCT01435096 | Phase 1 | Malignant Solid Tumour |
Latest
No recent events.
Follow Bn80927 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.